How should psychotherapy proceed when adjoined with psychedelics?
Marc J. Weintraub, David J. Miklowitz
World Psychiatry January 12, 2024 DOI: 10.1002/wps.21170 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Keywords | Psychotherapist Medline |
| Citations | 6 |
| Key points | Argues that psychedelic-assisted therapy (PAT) - comprising preparation, drug administration, and integration - has retained the same basic assumptions and methods since the 1950s, even as the treatment of mental disorders has notably advanced. |
Abstract
Over the past few years, research and public interest in psychedelic agents – such as psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) – for mental health purposes has skyrocketed. The therapeutic approach to the use of these agents involves three components: preparation, drug administration, and integration. This bundled treatment has been termed psychedelic-assisted therapy (PAT). The basic assumptions and methods of PAT, however, have remained unchanged since the 1950s, despite notable advances in the treatment of mental disorders.
Citations in the library
Cited by 6
- Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper European Psychiatry 2025
- Not a Standalone Treatment: Considerations for Psychedelic‐Assisted Therapy Brain and Behavior April 1, 2026
- Balancing Innovation and Evidence: Reflections on Structured Protocols in MDMA-Assisted Therapy Versus a Principle-Guided, Patient-Directed Approach Psychedelic Medicine March 10, 2026
- Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial. Journal of Affective Disorders June 15, 2026
- Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder. Journal of Psychiatric Practice May 1, 2025
and 1 more in the library
Cites 3
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up Journal of Psychopharmacology February 1, 2022
- Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development Psychedelic Medicine September 6, 2023